1. Home
  2. ASNS vs DRMA Comparison

ASNS vs DRMA Comparison

Compare ASNS & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Actelis Networks Inc.

ASNS

Actelis Networks Inc.

HOLD

Current Price

$2.45

Market Cap

10.9M

ML Signal

HOLD

Logo Dermata Therapeutics Inc.

DRMA

Dermata Therapeutics Inc.

HOLD

Current Price

$2.68

Market Cap

2.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASNS
DRMA
Founded
1998
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.9M
2.1M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
ASNS
DRMA
Price
$2.45
$2.68
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$50.00
$10.00
AVG Volume (30 Days)
139.5K
102.5K
Earning Date
11-14-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,367,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$208.63
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.41
$2.34
52 Week High
$17.80
$23.70

Technical Indicators

Market Signals
Indicator
ASNS
DRMA
Relative Strength Index (RSI) 53.86 38.67
Support Level $2.55 $2.66
Resistance Level $3.10 $2.98
Average True Range (ATR) 0.32 0.29
MACD -0.11 0.03
Stochastic Oscillator 5.61 35.37

Price Performance

Historical Comparison
ASNS
DRMA

About ASNS Actelis Networks Inc.

Actelis Networks Inc is a networking solutions company with a mission to enable communication for Internet of Things, or IoT, projects, deployed over wide areas such as cities, campuses, airports, military bases, roads, and rail. Its networking solutions use a combination of newly deployed fiber infrastructure and existing copper and coaxial lines to create a cost-effective, secure, and quick-to-deploy network. Its solutions also offer end-to-end network security to protect critical IoT data, utilizing a powerful combination of coding and encryption technologies, applied as required on both new and existing infrastructure within the hybrid-fiber-copper network. The company operates as one operating segment: developing and marketing access broadband equipment for copper and fiber networks.

About DRMA Dermata Therapeutics Inc.

Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.

Share on Social Networks: